See more : Gaming Innovation Group Inc. (GIG.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Enliven Therapeutics, Inc. (ELVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enliven Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Truist Financial Corporation (TFC-PO) Income Statement Analysis – Financial Results
- Environmental Impact Acquisition Corp. (ENVI) Income Statement Analysis – Financial Results
- PT Charnic Capital Tbk (NICK.JK) Income Statement Analysis – Financial Results
- Wally World Media, Inc. (WLYW) Income Statement Analysis – Financial Results
- SIMMTECH Co., Ltd. (222800.KQ) Income Statement Analysis – Financial Results
Enliven Therapeutics, Inc. (ELVN)
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 297.00K | 622.00K | 99.00K | 97.00K | 33.00K | 0.00 | 0.00 |
| Gross Profit | -297.00K | -622.00K | -99.00K | -97.00K | -33.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.57M | 31.02M | 20.47M | 8.24M | 19.01M | 8.24M | 7.92M |
| General & Administrative | 18.96M | 7.77M | 4.29M | 1.08M | 5.11M | 2.44M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -33.00K | 0.00 | 0.00 |
| SG&A | 18.96M | 7.77M | 4.29M | 1.08M | 5.07M | 2.44M | 987.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.68M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.08M | 10.68M | 8.91M |
| Cost & Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.12M | 10.68M | 8.91M |
| Interest Income | 11.97M | 1.13M | 22.00K | 31.00K | 578.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 97.00K | 33.00K | -660.00K | 0.00 |
| EBITDA | -81.93M | -38.58M | -24.65M | -9.27M | -23.43M | -11.34M | 221.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.53M | -38.79M | -24.76M | -9.32M | -24.12M | -10.68M | -8.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.95M | 1.13M | 22.00K | -9.65M | 653.00K | -660.00K | 9.13M |
| Income Before Tax | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | 221.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 88.00K | -22.00K | -31.00K | 653.00K | -821.14K | 221.00K |
| Net Income | -71.58M | -37.75M | -24.72M | -18.94M | -23.46M | -11.34M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| EPS Diluted | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| Weighted Avg Shares Out | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| Weighted Avg Shares Out (Dil) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact Robert S.
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
Imara Reports Full Year 2020 Financial Results and Business Highlights
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host...
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, Ph.D., President...
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin,...
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical data from the ongoing...
Source: https://incomestatements.info
Category: Stock Reports